

CAPCELL PAK C₁₈ KG

CAPCELL PAK: Our Most Durable Grade



 OSAKA SODA

CAPCELL PAK C₁₈ KG


■ Product Features

- Enhanced durability achieved through improvements in silica and the development of a new polymer coating technology
- Wide pH compatibility (usable pH range of 1 to 12)
- Designed to meet rigorous demands modern analytical condition

■ Physical properties

Functional group	Pore Size (Å)	Particle Size (μm)	Surface Area (m ² /g)	% of Carbon	Density (μmol/m ²)	Pressure resistance (MPa)	pH range	USP class No.
C18	100	2	320	17	2.7	100	1~12	L1
C18	100	3	320	17	2.7	20 / 50	1~12	L1
C18	100	5	320	17	2.7	20	1~12	L1

■ Hydrophobicity and surface polarity



■ Relationship between flow rate and theoretical plates: Basic compound analysis

The CAPCELL PAK C₁₈ KG S2 demonstrates superior performance compared to the hybrid-type C₁₈ columns from Company A and Company B. It minimizes performance degradation under high flow rate conditions while enabling low-pressure operation.




Figure 1: Relationship between flow rate and theoretical plates of amitriptyline

HPLC Conditions	
Column size	: 2.1 mm i.d. × 50 mm
Mobile phase	: 20 mmol/L Phosphate buffer (KH ₂ PO ₄ : K ₂ HPO ₄ = 1 : 1 in molar ratio) / CH ₃ OH = 20 / 80
Temperature	: 40 °C
Detection	: UV 220 nm
Inj. vol.	: 1 μL
Sample	: Amitriptyline (100 μg/mL)

■ Low bleed column

Compared to the conventional LC-MS/MS C₁₈ column, CAPCELL PAK C₁₈ MGIII, this CAPCELL PAK C₁₈ KG achieves a significant reduction in column bleeding, making it an ideal choice for LC-MS/MS analysis.






Figure 2: Relationship between flow rate and pressure

■ Durability under acidic (TFA) mobile phase conditions

The CAPCELL PAK C₁₈ KG demonstrates stable performance even under mobile phase conditions using the strong acid trifluoroacetic acid (TFA).




HPLC Conditions

Column : CAPCELL PAK C₁₈ KG S2 ; 2.1 mm i.d.× 50 mm
Mobile phase : A) 0.1 vol% TFA B) 0.1 vol% TFA, CH₃CN
B 25 % (0 min)-> 70 % (4 min)-> 25 % (4.1 min) Gradient
Flow rate : 600 μL/min
Temperature : 40 °C
Detection : UV 220 nm
Inj. vol. : 2 μL
Sample : 1. Ambroxol (20 μg/mL) 2. Epinastine (20 μg/mL) 3. Olopatadine (10 μg/mL)
4. Diphenhydramine (20 μg/mL) 5. Sulindac (15 μg/mL) 6. Fexofenadine (40 μg/mL)
7. Ketoprofen (20 μg/mL) 8. Flurbiprofen (20 μg/mL)
9. Diclofenac (10 μg/mL) 10. Ibuprofen (20 μg/mL)

■ Durability in continuous injections of pharmaceutical additive plasma samples

In bioanalytical sample analysis, a primary cause of column degradation is the adsorption of matrix-derived components onto the packing material surface. The CAPCELL PAK C₁₈ KG maintains excellent performance even under such Demanding conditions, ensuring stable operation during continuous injections.




HPLC Conditions

Column : CAPCELL PAK C₁₈ KG S2 ; 2.1 mm i.d.× 50 mm
Mobile phase : A) 0.1 vol% HCOOH B) 0.1 vol% HCOOH, CH₃CN
B 30 % (0 min)-> 90 % (2 min)-> 90 % (3 min)-> 30 % (3.1 min) Gradient
Flow rate : 600 μL/min
Temperature : 40 °C
Detection : UV 220 nm
Inj. vol. : 2 μL
Sample : 1. Febuxostat (10 μg/mL in human plasma supernatant)

■ Example of blonanserin analysis

Under the acidic conditions commonly used in LC-MS/MS, the CAPCELL PAK C₁₈ KG achieves excellent peak shapes for the analysis of the basic compound blonanserin.




HPLC Conditions

Column size : 4.6 mm i.d.× 150 mm
Mobile phase : 0.1 vol% HCOOH / CH₃OH = 30 / 70
Flow rate : 1.0 mL/min
Temperature : 40 °C
Detection : UV 254 nm
Sample : 1. Blonanserin (50 μg/mL)

■ Analysis of basic compounds under acidic, neutral, and basic conditions

Excellent peak shapes are achieved under acidic, neutral, and basic conditions.




HPLC Conditions

Column : CAPCELL PAK C₁₈ KG S3 ; 4.6 mm i.d.× 150 mm
Mobile phase : (pH 2) 20 mmol/L Phosphate buffer / CH₃CN = 40 / 60
(pH 7) 20 mmol/L Phosphate buffer / CH₃CN = 40 / 60
(pH 11.5) 20 mmol/L Na₂B₄O₇·10H₂O / CH₃CN = 40 / 60
Flow rate : 1.0 mL/min
Temperature : 30 °C
Detection : UV 254 nm
Inj. vol. : 5 μL
Sample : Amitriptyline (100 μg/mL)

■ Improved durability under alkaline mobile phase conditions

Compared to conventional C₁₈ columns, C₁₈ KG demonstrates superior durability with high reproducibility in separation performance and retention times even after 300 consecutive injections.



Enhanced durability under high-temperature and high-pH conditions

Sequence

5'-U^C^A^U^C^A^C^A^C^A^C^A^U^G^A^A^U^A^C^C^C^A^A^U^3' RNA 20 mer, All PS
5'-G^U^C^A^U^C^A^C^A^C^A^C^A^U^G^A^A^U^A^C^A^A^U^3' RNA 21 mer, All PS

^A = Phosphorothioated


HPLC Conditions

Column : CAPCELL PAK C₁₈ KG S3 ; 2.1 mm i.d.× 100 mm
Mobile phase : A) 15 mmol/L DBA, 50 mmol/L HFIP
B) 15 mmol/L DBA, 50 mmol/L HFIP, 50 vol% CH₃OH
B 73 % (0 min)-> 78 % (20 min)-> 73 % (20.1 min) Gradient
Flow rate : 200 μL/min
Temperature : 60 °C
Detection : UV 270 nm
Inj. vol. : 2 μL
Sample : 100 μg/mL each in 10 mmol/L Tris-HCl buffer (pH 8)

Application

■ Oligonucleotide Resolution Standard

This example demonstrates the analysis of the Oligonucleotide Resolution Standard (manufactured by Agilent), which is commonly used as a benchmark for column separation performance in oligonucleotide analysis, using the metal-free C₁₈ column, CAPCELL PAK INERT C₁₈ KG S3 (2.0 mm i.d. x 100 mm).




HPLC Conditions

Column	: CAPCELL PAK INERT C ₁₈ KG S3 ; 2.0 mm i.d. x 100 mm
Mobile phase	: A) H ₂ O / HFIP* / TEA** = 1000 / 30 / 0.4 B) CH ₃ OH / HFIP* / TEA** = 1000 / 30 / 2 B 15 % (0 min) -> 25 % (10 min) Gradient
Flow rate	: 0.4 mL/min
Temperature	: 60 °C
Detection	: UV 260 nm
Inj. vol.	: 2 µL
Sample dissolved in	: H ₂ O

HFIP* : 1,1,1,3,3,3-Hexafluoroisopropanol
TEA** : Triethylamine
※ 1 µg/mL = 1 ppm

■ Oligonucleotide Ladder Standard

This example demonstrates the analysis of the Oligonucleotide Ladder Standard (manufactured by Agilent), which is commonly used as a benchmark for evaluating column selectivity and reproducibility in oligonucleotide analysis, using the metal-free C₁₈ column, CAPCELL PAK INERT C₁₈ KG S3 (2.0 mm i.d. x 100 mm).





HPLC Conditions

Column	: CAPCELL PAK INERT C ₁₈ KG S3 ; 2.0 mm i.d. x 100 mm
Mobile phase	: A) H ₂ O / HFIP* / TEA** = 1000 / 30 / 0.4 B) CH ₃ OH / HFIP* / TEA** = 1000 / 30 / 2 B 20 % (0 min) -> 30 % (10 min) Gradient
Flow rate	: 0.4 mL/min
Temperature	: 60 °C
Detection	: UV 260 nm
Inj. vol.	: 2 µL
Sample dissolved in	: H ₂ O

HFIP* : 1,1,1,3,3,3-Hexafluoroisopropanol
TEA** : Triethylamine
※ 1 µg/mL = 1 ppm

■ Tyrosine kinase inhibitor

In reversed-phase mode analysis of basic compounds, peak distortion such as tailing can be a concern when the mobile phase is neutral or acidic. Here, this example demonstrates the analysis of three tyrosine kinase inhibitors under strongly alkaline conditions using the CAPCELL PAK C₁₈ KG S3 (4.6 mm i.d. x 100 mm), which has a useable wide pH range from 1 to 12.





HPLC Conditions

Column	: CAPCELL PAK C ₁₈ KG S3 ; 4.6 mm i.d. x 100 mm
Mobile phase	: A) 10 mmol/L K ₂ HPO ₄ (adjusted at pH 11.0 with potassium hydroxide) B) CH ₃ CN
Flow rate	B 0 % (0 min) -> 40 % (15 min) Gradient
Temperature	: 40 °C
Detection	: UV 254 nm
Inj. vol.	: 5 µL
Sample dissolved in	: 50 vol% CH ₃ OH
	※ 1 µg/mL = 1 ppm

■ Membrane protein solubilizer

The CAPCELL PAK C₁₈ KG, which achieves a significant reduction in column bleeding, is highly suitable for analysis in combination with the universal detector NQAD. Here, this example demonstrates the analysis of the challenging-to-detect compound BIGCHAP using the CAPCELL PAK C₁₈ KG S3 (4.6 mm i.d. x 150 mm) together with the NQAD detector.





HPLC Conditions

Column	: CAPCELL PAK C ₁₈ KG S3 ; 4.6 mm i.d. x 150 mm
Mobile phase	: H ₂ O / CH ₃ CN = 70 / 30
Flow rate	: 1.0 mL/min
Temperature	: 40 °C
Detection	: RI, UV 210 nm
Detector	: NQAD (Evaporation 35 °C, Nebulizer 30 °C)
Inj. vol.	: 5 µL
Sample dissolved in	: BIGCHAP was dissolved in 50 vol% methanol at 1 mg/mL. To 10 µL of this solution water was added to make 1 mL. ※ 1 µg/mL = 1 ppm


Application

■ Monoterpene compounds


Here is an example of HPLC analysis of four monoterpene acetate esters, which are structural isomers. The peak observed between Peak 1 and Peak 2 is presumed to be isobornyl acetate, which is present at approximately 20% in the commercially available bornyl acetate reagent.




1. Bornyl acetate
(2500 µg/mL) (M.W. 196.3)




Isobornyl acetate (M.W. 196.3)



2. Linalyl acetate
(50 µg/mL) (M.W. 196.3)



3. Neryl acetate
(50 µg/mL) (M.W. 196.3)





4. Geranyl acetate
(50 µg/mL) (M.W. 196.3)

HPLC Conditions


Column : CAPCELL PAK C₁₈ KG S5 ; 4.6 mm i.d. × 250 mm
Mobile phase : H₂O / CH₃CN = 30 / 70
Flow rate : 1.0 mL/min
Temperature : 40 °C
Detection : UV 210 nm
Inj. vol. : 10 µL
Sample dissolved in : 80 vol% CH₃CN
※ 1 µg/mL = 1 ppm

■ Steroids


Additionally, this example demonstrates the analysis of three steroids: prednisolone, hydrocortisone, and cortisone.



1. Prednisolone
(100 µg/mL) (M.W. 360.4)



2. Hydrocortisone
(100 µg/mL) (M.W. 362.5)



3. Cortisone
(100 µg/mL) (M.W. 360.4)

HPLC Conditions



Column : CAPCELL PAK C₁₈ KG S5 ; 4.6 mm i.d. × 250 mm
Mobile phase : H₂O / CH₃CN = 70 / 30
Flow rate : 1.0 mL/min
Temperature : 40 °C
Detection : UV 254 nm
Inj. vol. : 5 µL
Sample dissolved in : Prednisolone was dissolved in methanol at 2 mg/mL.
Hydrocortisone and cortisone were separately dissolved in methanol at 1 mg/mL.
50 µL of prednisolone solution and 100 µL of other solutions were mixed together
and water was added to the mixture to make 1 mL.
※ 1 µg/mL = 1 ppm

Column selection criteria for the 18th Edition of the Japanese Pharmacopoeia, Second Supplement

■ Column selection criteria for the quantitative determination of tolvaptan

Tolvaptan, a diuretic listed in the 18th Edition of the Japanese Pharmacopoeia, Second Supplement, has specific column selection criteria defined in the pharmacopoeia. The criteria state that a column must elute tolvaptan and hexyl para-hydroxybenzoate in that order, with a resolution of at least 15 between the two compounds.

With the introduction of the General Chapter on Chromatography in the 18th Edition of the Japanese Pharmacopoeia, First Supplement, parameters such as column dimensions and flow rates can now be adjusted, providing greater flexibility in column selection for quantitative analysis. Although the pharmacopoeia specifies a C₁₈ column with dimensions of 6.0 mm i.d. x 150 mm and a particle size of 5 µm for the quantitative determination of tolvaptan, the CAPCELL PAK C₁₈ KG S5 (4.6 mm i.d. x 150 mm) is also suitable. Using this column for the quantitative method achieved a resolution of 22.1, demonstrating excellent separation.



1. Tolvaptan
(100 µg/mL) (M.W. 448.9)



2. Hexyl 4-Hydroxybenzoate
(60 µg/mL) (M.W. 222.3)

HPLC Conditions

Column	: CAPCELL PAK C ₁₈ S5 ; 4.6 mm i.d. x 150 mm
Mobile phase	: H ₃ PO ₄ / H ₂ O / CH ₃ CN = 1 / 400 / 600
Flow rate	: 0.51 mL/min
Temperature	: 25 °C
Detection	: UV 254 nm
Inj. vol.	: 6 µL
Sample dissolved in	: CH ₃ OH
	* 1 µg/mL = 1 ppm

■ Column selection criteria for the purity test of tolvaptan

Tolvaptan, a diuretic listed in the 18th Edition of the Japanese Pharmacopoeia, Second Supplement, has specific column selection criteria defined in the pharmacopoeia. The criteria state that a column must elute tolvaptan and hexyl para-hydroxybenzoate in that order, with a resolution of at least 3 between the two compounds. Under these conditions, the CAPCELL PAK C₁₈ KG S3 (4.6 mm i.d. x 100 mm) achieved a resolution of 9.2, demonstrating excellent separation performance.



1. Tolvaptan
(40 µg/mL) (M.W. 448.9)

2. Isoamyl 4-Hydroxybenzoate
(30 µg/mL) (M.W. 208.3)

HPLC Conditions

Column	: CAPCELL PAK C ₁₈ KG S3 ; 4.6 mm i.d. x 100 mm
Mobile phase	: A) 0.1 vol% H ₃ PO ₄ B) 0.1 vol% H ₃ PO ₄ , CH ₃ CN
	B 40 % (0 min) > 80 % (20 min) > 80 % (25 min) > 40 % (25.1 min) Gradient
Flow rate	: 1.0 mL/min
Temperature	: 25 °C
Detection	: UV 254 nm
Inj. vol.	: 5 µL
Sample dissolved in	: CH ₃ OH
	* 1 µg/mL = 1 ppm

Product Lineup

CAPCELL PAK C₁₈ KG 2μm

Product number	Particle Size(μm)	Inner diameter(mm)	Length(mm)
85101	2	2.1	35
85102	2	2.1	50
85103	2	2.1	100
85104	2	2.1	150

CAPCELL PAK C₁₈ KG 3μm

Product number	Particle Size(μm)	Inner diameter(mm)	Length(mm)
85201	3	2.1	35
85202	3	2.1	50
85203	3	2.1	75
85204	3	2.1	100
85205	3	2.1	150
85206	3	2.1	250
85207	3	3.0	35
85208	3	3.0	50
85209	3	3.0	75
85210	3	3.0	100
85211	3	3.0	150
85212	3	3.0	250
85213	3	4.6	35
85214	3	4.6	50
85215	3	4.6	75
85216	3	4.6	100
85217	3	4.6	150
85218	3	4.6	250

CAPCELL PAK INERT C₁₈ KG

Product number	Particle Size(μm)	Inner diameter(mm)	Length(mm)
95093	2	2.0	50
95094	2	2.0	100
95095	2	2.0	150
95083	3	2.0	50
95084	3	2.0	100
95085	3	2.0	150

CAPCELL PAK C₁₈ KG 5μm


Product number	Particle Size(μm)	Inner diameter(mm)	Length(mm)
85301	5	2.1	35
85302	5	2.1	50
85303	5	2.1	75
85304	5	2.1	100
85305	5	2.1	150
85306	5	2.1	250
85307	5	3.0	35
85308	5	3.0	50
85309	5	3.0	75
85310	5	3.0	100
85311	5	3.0	150
85312	5	3.0	250
85313	5	4.6	35
85314	5	4.6	50
85315	5	4.6	75
85316	5	4.6	100
85317	5	4.6	150
85318	5	4.6	250

CAPCELL PAK C₁₈ KG Semi-Preparative Columns

Product number	Particle Size(μm)	Inner diameter(mm)	Length(mm)
85320	5	10	100
85321	5	10	150
85322	5	10	250
85324	5	20	100
85325	5	20	150
85326	5	20	250
85330	5	30	250

Inert Column Structure

Metal-Free Columns



Osaka Soda Co., Ltd.

Sales Department, Health Care Division

silica@osaka-soda.co.jp

<https://sub.osaka-soda.co.jp/HPLC/e/>